Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBLB612 for Neutropenia Prophylaxis in Breast Cancer
NCT02778763Phase 2Completed
- Sponsor
- BioLab Holdings
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Cyclic Peptides, Peptide Conjugates, Antimicrobial Peptides
01
Overview
A Phase 2 trial of CBLB612 in neutropenia, sponsored by BioLab Holdings. Started Dec 2015; status: completed.
02
Drugs
CBLB612
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02778763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778763.